Next-generation sequencing has emerged as the preferred approach for comprehensive genomic profiling in cancer.
Less than 20 percent of late-stage cancer patients receive the molecular tumor testing necessary to help guide treatment strategies. PGDx elio tissue complete, an FDA 510(k) cleared and CE-IVD marked decentralized pan solid tumor CGP test, demonstrated high concordance with the Foundation Medicine FoundationOne test.
This white paper from PGDx presents results from a study comparing the PGDx elio tissue complete Test to send-out testing for comprehensive genomic profiling, finding it to be a viable local testing solution for molecular laboratories and may thereby increase patient access to accurate tumor profiling at a faster turnaround time.
Offered Free by: PGDx
See All Resources from: PGDx